Skip to main content

Advertisement

Springer Nature Link
Log in

Anti-tumour efficacy of mitofusin-2 in urinary bladder carcinoma

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Mitochondrial GTPase mitofusin-2 gene (Mfn2) is a novel gene characterised as a cell proliferation inhibitor. Mfn2 protein over-expression, mediated by an adenovirus, has a significant anti-tumour effect in A548 and HT-29 cells. However, there is no report on the effect of Mfn2 on urinary bladder carcinoma (UBCC). In this study, we sought to investigate the function of Mfn2 in UBCC. Mfn2 expression in 36 paired UBCC samples was investigated by reverse transcription-polymerase chain reaction and Western blot analyses. An adenovirus encoding the complete Mfn2 open reading frame (Ad-Mfn2) was used to infect UBCC cells, and an adenoviral vector encoding green fluorescent protein (Ad-GFP) was used as a control. The effects of Mfn2 on cell-cycle distribution and apoptosis were assessed by flow cytometry and Western blot analyses. The Mfn2 protein showed significantly lower expression in UBCC tissues than nearby non-tumourous tissues. Ad-Mfn2 exhibited a significant anti-tumour effect in T24 and 5,637 cells. Mfn2 overexpression in T24 cells significantly inhibited cell proliferation, by arresting the transition of the cell cycle from the G1 to S phase, and induced apoptosis by upregulating active caspase-3 and cleaved PARP levels. Mfn2 also induced increased p21 and p27 expression levels, but down-regulated PCNA levels. These findings indicate that Mfn2 is a potential UBCC tumour suppressor gene, which showed significantly lower expression in tumour tissues than adjacent non-tumourous tissues and could promote apoptosis and inhibit the proliferation of UBCC cells. Mfn2 may become an important therapeutic target for treating UBCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Canada)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Parkin DM. The global burden of urinary bladder cancer. Scand J Urol Nephrol Suppl. 2008;218:12–20.

    Article  PubMed  Google Scholar 

  2. Stein JP, Grossfeld GD, Ginsberg DA, Esrig D, Freeman JA, Figueroa AJ, et al. Prognostic markers in bladder cancer: a contemporary review of the literature. J Urol. 1998;160(3 Pt 1):645–59.

    PubMed  CAS  Google Scholar 

  3. Sanchez-Carbayo M. Recent advances in bladder cancer diagnostics. Clin Biochem. 2004;37(7):562–71.

    Article  PubMed  CAS  Google Scholar 

  4. Kausch I, Bohle A. Molecular aspects of bladder cancer III. Prognostic markers of bladder cancer. Eur Urol. 2002;41(1):15–29.

    Article  PubMed  CAS  Google Scholar 

  5. Dey P. Urinary markers of bladder carcinoma. Clin Chim Acta. 2004;340(1–2):57–65.

    Article  PubMed  CAS  Google Scholar 

  6. Chen G, Zhang C, Zhu Y. Cloning and expression of a novel gene related to hypertension. Zhonghua Yi Xue Za Zhi. 1997;77(11):823–8.

    PubMed  CAS  Google Scholar 

  7. Chen KH, Guo X, Ma D, Guo Y, Li Q, Yang D, et al. Dysregulation of HSG triggers vascular proliferative disorders. Nat Cell Biol. 2004;6(9):872–83.

    Article  PubMed  CAS  Google Scholar 

  8. Karbowski M, Norris KL, Cleland MM, Jeong SY, Youle RJ. Role of Bax and Bak in mitochondrial morphogenesis. Nature. 2006;443(7112):658–62.

    Article  PubMed  CAS  Google Scholar 

  9. Karbowski M, Lee YJ, Gaume B, Jeong SY, Frank S, Nechushtan A, et al. Spatial and temporal association of Bax with mitochondrial fission sites, Drp1, and Mfn2 during apoptosis. J Cell Biol. 2002;159(6):931–8.

    Article  PubMed  CAS  Google Scholar 

  10. Wu L, Li Z, Zhang Y, Zhang P, Zhu X, Huang J, et al. Adenovirus-expressed human hyperplasia suppressor gene induces apoptosis in cancer cells. Mol Cancer Ther. 2008;7(1):222–32.

    Article  PubMed  CAS  Google Scholar 

  11. Landman J, Chang Y, Kavaler E, Droller MJ, Liu BC. Sensitivity and specificity of NMP-22, telomerase, and BTA in the detection of human bladder cancer. Urology. 1998;52(3):398–402.

    Article  PubMed  CAS  Google Scholar 

  12. Schmetter BS, Habicht KK, Lamm DL, Morales A, Bander NH, Grossman HB, et al. A multicenter trial evaluation of the fibrin/fibrinogen degradation products test for detection and monitoring of bladder cancer. J Urol. 1997;158(3 Pt 1):801–5.

    PubMed  CAS  Google Scholar 

  13. Bagchi A, Mills AA. The quest for the 1p36 tumor suppressor. Cancer Res. 2008;68(8):2551–6.

    Article  PubMed  CAS  Google Scholar 

  14. Steidl C, Simon R, Burger H, Brinkschmidt C, Hertle L, Bocker W, et al. Patterns of chromosomal aberrations in urinary bladder tumours and adjacent urothelium. J Pathol. 2002;198(1):115–20.

    Article  PubMed  Google Scholar 

  15. Matsumoto H, Matsuyama H, Fukunaga K, Yoshihiro S, Wada T, Naito K. Allelic imbalance at 1p36 may predict prognosis of chemoradiation therapy for bladder preservation in patients with invasive bladder cancer. Br J Cancer. 2004;91(6):1025–31.

    PubMed  CAS  Google Scholar 

  16. Guo Y, Xiao P, Lei S, Deng F, Xiao GG, Liu Y, et al. How is mRNA expression predictive for protein expression? A correlation study on human circulating monocytes. Acta Biochim Biophys Sin (Shanghai). 2008;40(5):426–36.

    Article  CAS  Google Scholar 

  17. Teng J, Wang ZY, Jarrard DF, Bjorling DE. Roles of estrogen receptor alpha and beta in modulating urothelial cell proliferation. Endocr Relat Cancer. 2008;15(1):351–64.

    Article  PubMed  CAS  Google Scholar 

  18. Stein JP, Ginsberg DA, Grossfeld GD, Chatterjee SJ, Esrig D, Dickinson MG, et al. Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. J Natl Cancer Inst. 1998;90(14):1072–9.

    Article  PubMed  CAS  Google Scholar 

  19. Philipp-Staheli J, Payne SR, Kemp CJ. p27(Kip1): regulation and function of a haploinsufficient tumor suppressor and its misregulation in cancer. Exp Cell Res. 2001;264(1):148–68.

    Article  PubMed  CAS  Google Scholar 

  20. Maga G, Hubscher U. Proliferating cell nuclear antigen (PCNA): a dancer with many partners. J Cell Sci. 2003;116(Pt 15):3051–60.

    Article  PubMed  CAS  Google Scholar 

  21. Moldovan GL, Pfander B, Jentsch S. PCNA, the maestro of the replication fork. Cell. 2007;129(4):665–79.

    Article  PubMed  CAS  Google Scholar 

  22. Skopelitou A, Hadjiyannakis M, Dimopoulos D, Kamina S, Krikoni O, Alexopoulou V, et al. p53 and c-jun expression in urinary bladder transitional cell carcinoma: correlation with proliferating cell nuclear antigen (PCNA) histological grade and clinical stage. Eur Urol. 1997;31(4):464–71.

    PubMed  CAS  Google Scholar 

  23. Yoshikawa H, Ikeuchi T, Iguchi H, Onodera Y, Kai Y. Expression of PCNA/cyclin, p53, C-erbB-2 versus histological grade in transitional cell carcinoma of urinary bladder. Hinyokika Kiyo. 1995;41(4):253–8.

    PubMed  CAS  Google Scholar 

  24. Chen H, Detmer SA, Ewald AJ, Griffin EE, Fraser SE, Chan DC. Mitofusins Mfn1 and Mfn2 coordinately regulate mitochondrial fusion and are essential for embryonic development. J Cell Biol. 2003;160(2):189–200.

    Article  PubMed  CAS  Google Scholar 

  25. Guo X, Chen KH, Guo Y, Liao H, Tang J, Xiao RP. Mitofusin 2 triggers vascular smooth muscle cell apoptosis via mitochondrial death pathway. Circ Res. 2007;101(11):1113–22.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported by grants from Major Program of Science and Technology Bureau of Zhejiang Province (No. I20100034).

Author information

Authors and Affiliations

  1. Department of Urology, The First Affiliated Hospital, College of Medicine, Zhejiang University, 310003, Hangzhou, People’s Republic of China

    Baiye Jin, Guanghou Fu, Hao Pan, Jia Lv & Geming Chen

  2. Key Lab of Combined Multi-organ Transplantation, Ministry of Public Health, Key Lab of Organ Transplantation, Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, College of Medicine, Zhejiang University, 310003, Hangzhou, People’s Republic of China

    Xiaofei Cheng, Lin Zhou & Shusen Zheng

  3. The First Affiliated Hospital, College of Medicine, Zhejiang University, 79# Qingchun Road, 310003, Hangzhou, People’s Republic of China

    Shusen Zheng

Authors
  1. Baiye Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Guanghou Fu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hao Pan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xiaofei Cheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lin Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jia Lv
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Geming Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Shusen Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shusen Zheng.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jin, B., Fu, G., Pan, H. et al. Anti-tumour efficacy of mitofusin-2 in urinary bladder carcinoma. Med Oncol 28 (Suppl 1), 373–380 (2011). https://doi.org/10.1007/s12032-010-9662-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-010-9662-5

Keywords

Search

Navigation